Stealth Bio's neuromuscular disorder drug fails study 21st Century Cures Act, Age-Related Macular Degeneration, Barth Syndrome, Clinical Trials, Leber’s Hereditary Optic Neuropathy, Mitochondrial Disease, Mitochondrial Myopathy, Primary Mitochondrial Myopathy (PMM), Primary Mitochondrial Myopathy (PMM), Product Pipelines, R&D, Shares, Walking Stealth BioTherapeutics Corp.’s shares crashed after the company’s lead neuromuscular disorder product candidate failed to help patients walk better and reduce fatigue. Read more December 20, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-12-20 08:30:522019-12-20 08:30:52Stealth Bio's neuromuscular disorder drug fails study
